The GLP-1 effect on MedTech

GLP-1 receptor agonists have surged into the spotlight for their remarkable effectiveness in managing type 2 diabetes and obesity. However, despite widespread discussion among pharmaceutical experts and the general public, the impact of GLP-1 on the MedTech industry remains largely underexplored.

Through insights gleaned from this survey and comprehensive interviews with senior MedTech executives, this study delves into the implications of GLP-1's expansion for the MedTech sector.

Register now to download the report and learn strategic approaches for the MedTech industry to uncover new growth opportunities in this evolving environment.

One more step to download

Strategic implications for the MedTech industry

Published by:
Language:
English

Required fields are marked with an asterisk (*)

Producing high-quality publications such as „The GLP-1 effect on MedTech“ incurs costs at PwC and Strategy&. But instead of charging readers for this service, we have decided to make this publication available free of charge in return for your consent to marketing. Consenting to marketing will give you access to all the benefits offered by Strategy& and PwC’s Information Service, and you’ll get information tailored to your needs on a regular basis.

Upon submission of your consent and verification of your e-mail address, your consideration for receiving „The GLP-1 effect on MedTech“ is fulfilled and you have the right to unsubscribe at any time, e.g. by e-mail to de_datenschutz@pwc.com, thereby withdrawing your consent with effect for the future. You can find further information in this privacy policy.

Yes, I would like to receive the latest updates on consultancy advice and service information, news from my industry, notifications about upcoming events, information on PwC research and other marketing information from the PwC Network companies in the German-speaking region by e-mail.

My consent relates to the PwC Network companies in the German-speaking region listed here with their business purposes (hereinafter jointly referred to as „PwC DE“)

PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft | Auditing, tax consulting, economic and financial consulting, strategy consulting

PricewaterhouseCoopers Legal AG Rechtsanwaltsgesellschaft | Legal advice

Fachverlag Moderne Wirtschaft GmbH | Economic and financial advice through print and online publications

INTES Akademie für Familienunternehmen GmbH | Economic and financial advice for family businesses

PwC Strategy& (Germany) GmbH | Economic and strategic consulting

PwC Strategy& (Austria) GmbH | Economic and strategic consulting

PwC Cyber Security Services GmbH | Business and strategy consulting in the field of IT security (IT security services)

PwC Certification Services GmbH | Testing and certification with specialization in IT security, data protection and compliance

PwC Solutions GmbH | Distribution of IT solutions for management, economic and financial consulting

To individualise communication with me, I consent to PwC DE analysing my interests that I expressly communicate (e.g. via a web preference center on a PwC DE website) and my usage behaviour (e.g. retrieved content, access, clicks and reading time) with regard to newsletters and similar communications as well as via linked PwC DE websites, by using cookies, web-beacons and similar technologies, and may store this information in a personal profile. I further agree that PwC DE may also add my personal contact details (e.g. name, title, company and role/position) that I have entered on a PwC DE website and/or that are already stored in the customer relationship management systems operated by PwC DE to this profile. I finally agree that PwC DE may also add public company information about my employer to this profile.

*Submit consent and receive access to „The GLP-1 effect on MedTech“ in return.